ArticleAnalytical chemistry2025
A Hit Prioritization Strategy for Compound Library Screening Using LiP-MS and Molecular Dynamics Simulations Applied to KRas G12D Inhibitors.
Article in Analytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- 3D Proteomics: Structural, Functional, Chemical and Biomarker Discovery Proteomics With LiP-MS.Molecular & cellular proteomics : MCP · 2026Review
- Characterization of the KRas G12D-inhibitor interactions by differential HDX-MS and molecular dynamics simulations.Computational and structural biotechnology journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An important step in screening small-molecule libraries for drug discovery is hit prioritization and validation in order to rule out false positives. This is usually performed using biochemical and biophysical assays, so the development of orthogonal assays that are highly sensitive and can accelerate the hit-to-lead process would be valuable. Limited proteolysis combined with mass spectrometry (LiP-MS) is a technique used to study changes in protein structure upon ligand binding. In LiP-MS, proteins are exposed to low concentrations of proteases under native conditions. The resulting proteolytic patterns are sensitive to the protein structure near the cleavage site, which can change upon ligand binding. We have characterized the interaction of small-molecule inhibitors of the KRas G12D mutant oncoprotein by LiP-MS combined with molecular dynamics (MD). Intact mass spectrometry and top-down analysis were used to detect and identify KRas G12D cleavage products in the presence and absence of inhibitors, thereby locating the cleavage sites within the protein. Cleavage sites that were found to be protected upon compound binding correlated well with the switch II binding site. The degree of cleavage depended on the binding affinity and the presence of specific functional groups in the inhibitor's structure. A comparison of MD simulations for the ligand-free and ligand-bound proteins revealed the atomistic mechanisms by which the cleavage sites, located in flexible and disordered regions, were stabilized upon compound binding. We suggest that LiP-MS combined with MD (LiP-MS-MD) could be valuable in small-molecule screening campaigns and can be added to the current list of methods for high-quality hit selection in early stage drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.